Loading...
CCEL logo

Cryo-Cell International, Inc.NYSEAM:CCEL Stock Report

Market Cap US$28.7m
Share Price
US$3.60
US$8.5
57.6% undervalued intrinsic discount
1Y-28.4%
7D-1.9%
1D
Portfolio Value
​
View

Cryo-Cell International, Inc.

NYSEAM:CCEL Stock Report

Market Cap: US$28.7m

Cryo-Cell International (CCEL) Stock Overview

Engages in cord blood and cord tissue cryopreservation services in the United States. More details

CCEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Earnings are forecast to grow 128.57% per year

Risk Analysis

Interest payments are not well covered by earnings

Negative shareholders equity

Does not have a meaningful market cap ($29M)


CCEL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Cryo-Cell International, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cryo-Cell International
Historical stock prices
Current Share PriceUS$3.60
52 Week HighUS$6.35
52 Week LowUS$2.72
Beta0.57
1 Month Change-0.55%
3 Month Change22.45%
1 Year Change-28.43%
3 Year Change-40.40%
5 Year Change-61.70%
Change since IPO-56.36%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 17

Cryo-Cell International to transfer listing from Nasdaq to NYSE

Cryo-Cell International (NASDAQ:CCEL) on Wednesday said it would transfer its listing from the Nasdaq to the NYSE, effective Aug. 30. Oldsmar, Fla.-based CCEL is a private cord blood bank that separates and stores stem cells. According to the company, more than 500K parents from 87 countries have entrusted it with ‎their baby’s cord blood and cord tissue stem cells. "After careful evaluation, we concluded that the NYSE American stock exchange is a better fit for Cryo-Cell now and hope that it will result in a more liquid trading market for our shareholders," CCEL co-CEO David Portnoy said in a statement. CCEL said its last trading day on the Nasdaq is expected to be Aug. 29 and that its common stock would continued to trade under its existing symbol. Cryo-Cell (CCEL) stock was 7.3% lower to $5.33 after hours.
Seeking Alpha • Jul 11

CRYO-CELL International GAAP EPS of $0.08, revenue of $7.63M

CRYO-CELL International press release (NASDAQ:CCEL): Q2 GAAP EPS of $0.08. Revenue of $7.63M (+5.8% Y/Y).
Seeking Alpha • Feb 11

Cryo-Cell International: A Stable Business Paired With An Upcoming Catalyst

Cryo-Cell International has a stable business that generates consistent cash flow. The company is close to monetizing a partnership with Duke University to bring patented stem cell treatments to market. Cryo-Cell's operating cash flow is adequate to fund monetization expenses. Cryo-Cell has a long runway for growth if the Duke partnership pays off; if not, the company's valuation is still cheap relative to its operating performance. I see asymmetric upside potential and ample downside protection.

Shareholder Returns

CCELUS HealthcareUS Market
7D-1.9%2.0%2.2%
1Y-28.4%19.7%24.8%

Return vs Industry: CCEL underperformed the US Healthcare industry which returned 19.8% over the past year.

Return vs Market: CCEL underperformed the US Market which returned 23.5% over the past year.

Price Volatility

Is CCEL's price volatile compared to industry and market?
CCEL volatility
CCEL Average Weekly Movement9.9%
Healthcare Industry Average Movement7.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: CCEL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CCEL's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198974David Portnoywww.cryo-cell.com

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells.

Cryo-Cell International, Inc. Fundamentals Summary

How do Cryo-Cell International's earnings and revenue compare to its market cap?
CCEL fundamental statistics
Market capUS$28.68m
Earnings (TTM)-US$2.67m
Revenue (TTM)US$31.28m
0.9x
P/S Ratio
-10.9x
P/E Ratio

Is CCEL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CCEL income statement (TTM)
RevenueUS$31.28m
Cost of RevenueUS$11.41m
Gross ProfitUS$19.87m
Other ExpensesUS$22.54m
Earnings-US$2.67m

Last Reported Earnings

Feb 28, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin63.53%
Net Profit Margin-8.52%
Debt/Equity Ratio-53.9%

How did CCEL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 10:35
End of Day Share Price 2026/06/15 00:00
Earnings2026/02/28
Annual Earnings2025/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cryo-Cell International, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Allen KleeMaxim Group